open access

Vol 47, No 3 (2016)
Prace poglądowe / Reviews
Published online: 2016-07-01
Submitted: 2016-05-10
Get Citation

Recommendations for assessment of co-morbidities and tyrosine kinase inhibitor choice in patients suffering from chronic myeloid leukemia

Tomasz Sacha1, Sebastian Szmit2, Dorota Zozulińska-Ziółkiewicz3, Witold Prejzner4, Joanna Góra-Tybor5
DOI: 10.1016/j.achaem.2016.06.001
·
Acta Haematol Pol 2016;47(3):184-196.
Affiliations
  1. Katedra Hematologii Collegium Medicum Uniwersytetu Jagiellońskiego, Kraków, Polska
  2. Klinika Krążenia Płucnego i Chorób Zakrzepowo-Zatorowych, Centrum Medyczne Kształcenia Podyplomowego, Europejskie Centrum Zdrowia, Otwock, Polska
  3. Katedra i Klinika Chorób Wewnętrznych i Diabetologii, Uniwersytet Medyczny w Poznaniu, Szpital im. Fr. Raszei, Poznań, Polska
  4. Klinika Hematologii i Transpantologii Gdańskiego Uniwersytetu Medycznego, Gdańsk, Polska
  5. Instytut Hematologii i Transfuzjologii w Warszawie, Polska

open access

Vol 47, No 3 (2016)
Prace poglądowe / Reviews
Published online: 2016-07-01
Submitted: 2016-05-10

Abstract

Treatment of chronic myeloid leukemia with tyrosine kinase inhibitors (TKI) is very effective. The vast majority of patients achieve deep and long-lasting therapeutic responses including those on molecular level. Understanding the adverse effects of TKIs is of great importance during life-long therapy. The safety profile of TKI should be considered especially when used in patients suffering from various co-morbidities. In this paper, treatment recommendations for patients suffering from diabetes mellitus, atherosclerosis with circulation disturbances in peripheral arteries, congestive heart failure, pulmonary hypertension and pleural effusions are presented. Drug interactions between TKIs and medicaments used in the treatment of the above-mentioned co-morbidities are discussed.

Abstract

Treatment of chronic myeloid leukemia with tyrosine kinase inhibitors (TKI) is very effective. The vast majority of patients achieve deep and long-lasting therapeutic responses including those on molecular level. Understanding the adverse effects of TKIs is of great importance during life-long therapy. The safety profile of TKI should be considered especially when used in patients suffering from various co-morbidities. In this paper, treatment recommendations for patients suffering from diabetes mellitus, atherosclerosis with circulation disturbances in peripheral arteries, congestive heart failure, pulmonary hypertension and pleural effusions are presented. Drug interactions between TKIs and medicaments used in the treatment of the above-mentioned co-morbidities are discussed.

Get Citation

Keywords

Chronic myeloid leukemia; Tyrosine kinase inhibitors; Co-morbidities

About this article
Title

Recommendations for assessment of co-morbidities and tyrosine kinase inhibitor choice in patients suffering from chronic myeloid leukemia

Journal

Acta Haematologica Polonica

Issue

Vol 47, No 3 (2016)

Pages

184-196

Published online

2016-07-01

DOI

10.1016/j.achaem.2016.06.001

Bibliographic record

Acta Haematol Pol 2016;47(3):184-196.

Keywords

Chronic myeloid leukemia
Tyrosine kinase inhibitors
Co-morbidities

Authors

Tomasz Sacha
Sebastian Szmit
Dorota Zozulińska-Ziółkiewicz
Witold Prejzner
Joanna Góra-Tybor

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl